FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
AstraZeneca bags three of the month’s four oncology approvals.
On a wing and a prayer Leap heads for phase 3.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.